Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | KDM3B | Q7LBC6 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.35 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.35 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.35 |
| ▸ | FPR1 | P21462 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | F7 | P08709 | 1/20 | 0.32 |
| ▸ | F3 | P13726 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10823654 | 0.84 | PDE4A (0.38) | KDM4EKDM3BKMT2AALDH1A1SLC9A1 | |
| SCHEMBL10823648 | 0.80 | B3GNT2 (0.46) | KDM4EKDM3BKMT2AALDH1A1SLC9A1 | |
| SCHEMBL425896 | 0.80 | SLC9A1 (0.35) | KDM4EKDM3BKMT2AALDH1A1SLC9A1 | |
| SCHEMBL19812558 | 0.75 | KDM4E (0.41) | KDM4EKDM3BKMT2AALDH1A1CSNK2A1 | |
| SCHEMBL7586830 | 0.73 | ALDH1A1 (0.42) | KDM4EKDM3BKMT2AALDH1A1CSNK2A1 | |
| SCHEMBL14967362 | 0.73 | DAO (0.42) | KDM4EKMT2AALDH1A1MAPT | |
| SCHEMBL16863256 | 0.69 | KDM4E (0.41) | KDM4EKDM3BKMT2AALDH1A1CSNK2A1 | |
| SCHEMBL23882395 | 0.68 | CYP2C19 (0.58) | KDM4EKMT2AALDH1A1CSNK2A1CSNK2A2 | |
| SCHEMBL9054602 | 0.67 | KDM3B (0.39) | KDM4EKDM3BKMT2AALDH1A1CSNK2A1 | |
| SCHEMBL14969067 | 0.65 | MEN1 (0.53) | KDM4EKMT2AALDH1A1MAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 337 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2002531470-A | — | — | 2002-09-24 | — | — | JP | claimed |
| EP-1163374-A2 | ARRAYS OF ORGANIC COMPOUNDS ATTACHED TO SURFACES | Syntrix Biochip, Inc. (US) | 2001-12-19 | — | — | EP | claimed |
| WO-2000033084-A2 | ARRAYS OF ORGANIC COMPOUNDS ATTACHED TO SURFACES | SYNTRIX BIOCHIP, INC. (US) | 2000-06-08 | — | — | WO | claimed |
| WO-2026106695-A1 | TARGETED NANOPARTICLES ENCAPSULATING WATER-SOLUBLE THERAPEUTICS, METHODS OF PRODUCTION, AND USE | OPTIMEOS LIFE SCIENCES, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026098357-A1 | FREEZE-DRIED NUCLEIC ACID-LOADED LIPID NANOPARTICLE AND RECONSTITUTION METHOD THEREOF | KUDO BIOTECHNOLOGY, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260130987-A1 | VACCINATION AGAINST PNEUMOCCOCAL AND COVID-19 INFECTIONS | PFIZER INC. (US) | 2026-05-14 | — | — | US | disclosed |
| WO-2026088119-A1 | LIPIDATED TLR7/8 MODULATORS AS ADJUVANTS AND USES THEREOF | PFIZER INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260109977-A1 | MODIFIED RNA FOR INCREASING PROTEIN EXPRESSION | TRILINK BIOTECHNOLOGIES, LLC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4729614-A1 | SYSTEM AND METHOD FOR SEPARATING MRNA | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2026-04-22 | — | — | EP | disclosed |
| EP-4728076-A1 | METHOD FOR STABILIZING RNA | Pfizer Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4720094-A1 | MUTATED FRAGMENT OF VZV GLYCOPROTEIN E | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2026-04-08 | — | — | EP | disclosed |
| WO-2003016499-A2 | COMBINATORIAL METHODS FOR INDUCING CANCER CELL DEATH | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2003-02-27 | — | — | WO | disclosed |
| EP-1163374-A2 | ARRAYS OF ORGANIC COMPOUNDS ATTACHED TO SURFACES | Syntrix Biochip, Inc. (US) | 2001-12-19 | — | — | EP | disclosed |
| EP-1163520-A1 | POROUS COATINGS BEARING LIGAND ARRAYS | Syntrix Biochip, Inc. (US) | 2001-12-19 | — | — | EP | disclosed |
| US-6159681-A | Light-mediated method and apparatus for the regional analysis of biologic material | SYNTRIX BIOCHIP, INC. (US) | 2000-12-12 | — | — | US | disclosed |
| WO-2000033084-A2 | ARRAYS OF ORGANIC COMPOUNDS ATTACHED TO SURFACES | SYNTRIX BIOCHIP, INC. (US) | 2000-06-08 | — | — | WO | disclosed |
| WO-2000033078-A1 | POROUS COATINGS BEARING LIGAND ARRAYS | SYNTRIX BIOCHIP, INC. (US) | 2000-06-08 | — | — | WO | disclosed |
| WO-1999061653-A2 | LIGHT-MEDIATED REGIONAL ANALYSIS OF BIOLOGIC MATERIAL | SYNTRIX BIOCHIP (US) | 1999-12-02 | — | — | WO | disclosed |
| US-5705333-A | Peptide-based nucleic acid mimics(PENAMS) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-01-06 | — | — | US | disclosed |
| WO-1996004000-A1 | PEPTIDE-BASED NUCLEIC ACID MIMICS (PENAMs) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109977-A1 | MODIFIED RNA FOR INCREASING PROTEIN EXPRESSION | RNGTT, RNMT, UPF1 | KDM4E 461/4885KDM3B 721/4885KMT2A 1224/4885 |
| US-20260130987-A1 | VACCINATION AGAINST PNEUMOCCOCAL AND COVID-19 INFECTIONS | SARS1, CD14, PYCARD | KDM4E 4744/4885KDM3B 4627/4885KMT2A 4478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.